Shares of Greenwich LifeSciences, Inc. (GLSI) are up more than 6% Friday morning on robust immune response data from the Phase 2b study of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, over 5 years of follow-up.
The data were published at the American Association for Cancer Research (AACR) annual meeting.
GLSI, currently at $53.58, has been trading in the range of $3.26- $158.07 in the last one year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.